AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01265602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study NCT01265602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LASW1510
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study NCT01265602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of LAS41007
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study NCT00435279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg
Study NCT00435279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00435279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Study NCT04093674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: de-epithelized (DE) SCTG
Description: subepithelial connective tissue grafts
Study NCT03042858 — intervention group
Intervention type: OTHER
Intervention: Infants with PPV
Description: Data will be collected for up to 18 years to monitor for inguinal hernia.
Study NCT03042858 — intervention group
Intervention type: OTHER
Intervention: Infants without PPV
Description: Basic data will be collected regarding the surgery and the subject's study participation will be complete.
Study NCT00303017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid
Description: flavonoid mixture
Study NCT00303017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: non-steroidal anti-inflammatory drug
Study NCT00734851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
Study NCT00734851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
Study NCT00734851 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBXRT
Description: External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
Study NCT02259569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Study NCT02259569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume-controlled ventilation
Study NCT03941769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-7
Description: Given IM or SC
Study NCT05672680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
Study NCT05672680 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
Study NCT03386643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019
Description: The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
Study NCT03386643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05%
Description: The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
Study NCT01808079 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02322658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone Tablets 3 mg
Study NCT02322658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone Tablets 3 mg
Study NCT01528826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine plus oxaliplatin
Description: Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
Study NCT03604887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated.
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT210771
Description: An electronic cigarette
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT210751
Description: An electronic cigarette
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6T30134157764
Description: An electronic cigarette
Study NCT03503370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G41A7C071
Description: An electronic cigarette
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M011161212
Description: An electronic cigarette
Study NCT03294356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21002
Description: A combustible cigarette
Study NCT00894907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PiCCO-parameter-guided volume resuscitation
Description: Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI >12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP>65mmHg (MAP: Mean Arterial Pressure); IAPP >60mmHg (IAPP: Intra-abdominal Perfusion Pressure)
Study NCT00894907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control-group
Description: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP >65mmHg;IAPP >60mmHg
Study NCT02139514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Social Cognition Training
Description: Social skills training via virtual reality with trained therapist.
Study NCT02511236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
Study NCT02511236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
Study NCT03503370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
Study NCT02511236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
Study NCT02511236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
Study NCT04615442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epihunter
Description: Subjects wear epihunter during routine video EEG
Study NCT02123056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study NCT02123056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
Study NCT00790244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin , ifosfamide
Description: doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
Study NCT00790244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
Study NCT00790244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Study NCT00790244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, ifosfamide
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Study NCT01862250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Duraclon®)
Description: Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration
Study NCT01466803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Study NCT01148160 — intervention group
Intervention type: DRUG
Intervention: voriconazole
Description: intravenous, oral administration
Study NCT04542421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound use in patients hospitalized with COVID
Description: Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
Study NCT02644863 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
Study NCT02644863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
Study NCT02644863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
Study NCT02644863 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
Study NCT02644863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
Study NCT02207803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Study NCT03500783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
Study NCT03500783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPB
Description: Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
Study NCT03971955 — intervention group
Intervention type: OTHER
Intervention: Mixed Meal Test
Description: a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
Study NCT03971955 — intervention group
Intervention type: OTHER
Intervention: Dual Energy X-Ray Absorptiometry (DEXA)
Description: DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
Study NCT03971955 — intervention group
Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy
Description: The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
Study NCT03597750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repose®
Description: * Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors
Study NCT03884699 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant
Description: Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique.
Study NCT04449302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate molar implant with customized healing abutment
Description: Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done.
Study NCT04449302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate molar implant with customized healing abutment
Description: Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done.
Study NCT03109353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP with 5-aminolevulinic acid
Description: extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
Study NCT00931437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin K-rich dairy product
Description: several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
Study NCT01103258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high ligation and stripping (surgery)
Description: surgery consisting of high ligation in combination with long saphenous stripping
Study NCT01103258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FOAM
Description: duplex guided foam sclerotherapy
Study NCT03620123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
Study NCT03620123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: docetaxel 75 mg/m² intravenous infusion every three weeks
Study NCT01475851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK548470 300 mg tablet
Description: Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Study NCT00392743 — intervention group
Intervention type: PROCEDURE
Intervention: pet/spect scan
Study NCT04290416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microwire electrodes
Study NCT01024036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
Study NCT01024036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by 1-hour intravenous infusion every 3 weeks
Study NCT01024036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.